Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
about
A Cysteine Zipper Stabilizes a Pre-Fusion F Glycoprotein Vaccine for Respiratory Syncytial VirusViral Infection in the Development and Progression of Pediatric Acute Respiratory Distress SyndromeDiscovery and Characterization of Phage Display-Derived Human Monoclonal Antibodies against RSV F GlycoproteinWhat Are the Most Powerful Immunogen Design Vaccine Strategies?Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion GlycoproteinMatrix Metalloproteinase-9 Mediates RSV Infection in Vitro and in VivoPreventing hospitalizations for respiratory syncytial virus infectionStability Characterization of a Vaccine Antigen Based on the Respiratory Syncytial Virus Fusion Glycoprotein.Respiratory Syncytial Virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene.Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts.Down syndrome as risk factor for respiratory syncytial virus hospitalization: A prospective multicenter epidemiological study.First versus second year respiratory syncytial virus prophylaxis in chronic lung disease (2005-2015).Respiratory Syncytial Virus Infection Rates with Limited Use of Palivizumab for Infants Born at 29 to 31+6/7 Weeks Gestational Age.Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention.Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adults.Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.Respiratory syncytial virus activity and climate parameters during a 12-year period.Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis.Aberrant T cell immunity triggered by human Respiratory Syncytial Virus and human Metapneumovirus infection.A population study of respiratory rehospitalisation in very preterm infants in the first 3 years of life.Advances in Vaccines to Prevent Viral Respiratory Illnesses in Children.Antibody-Induced Internalization of the Human Respiratory Syncytial Virus Fusion Protein.Antibodies to Staphylococcus aureus capsular polysaccharides 5 and 8 perform similarly in vitro but are functionally distinct in vivo.Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.Seasonality and geographical spread of respiratory syncytial virus epidemics in 15 European countries, 2010 to 2016.Structural basis for recognition of the central conserved region of RSV G by neutralizing human antibodies.Prévenir les hospitalisations pour l’infection par le virus respiratoire syncytial.The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.Removal of the N-Glycosylation Sequon at Position N116 Located in p27 of the Respiratory Syncytial Virus Fusion Protein Elicits Enhanced Antibody Responses after DNA Immunization
P2860
Q27305097-BABF4964-AA81-4C69-969A-2B54F5642FF7Q28071857-6D86FC29-1DCB-4518-B2DE-48891F9337FCQ28552644-9ABA9FB7-CEFB-4B85-B9D7-C681E79FE0B7Q28729792-568DD7D1-C14A-4D72-9A03-F4EDB48CE9A4Q35687662-79E9B08E-FA6E-460C-98E5-56429169A008Q36076225-7F9D3413-4786-4EFD-B90F-56F8B973EAA4Q36082195-C3A2972D-30CA-4420-951F-5C1874ED0333Q36169170-FB212C95-96BA-4729-B17E-4E46DDF82D0DQ36925097-FD7E96B2-83BF-4E50-8A53-4BE9041B52AEQ37049972-94175490-9EE5-4013-B60F-8330A9F9CF71Q37638396-E4AA5F0D-E8A3-4A64-8354-87F497F73253Q37660572-0FCF9D6E-8DA0-4F38-BD16-88183B307731Q37711133-B226D84F-5355-40B2-AC90-F3A5ECAE5784Q38604949-A49F01DA-96EF-4344-BC92-BA687A2D22D8Q38736222-9C6418E2-021B-48CA-85D1-192B462B5275Q38835118-BB2F8391-C565-4E9A-ABD0-F8534701D8B9Q38942083-7B714421-0268-4CF3-B5E6-FF7EC8FE56E4Q39025676-20B26F6B-2CC5-4E02-AACA-96EE989D53CBQ39027049-43A64DC6-60AE-4D16-AEC2-E59E035BB9DFQ39749614-4BD3C33D-6A77-480D-976E-5CB22D17AA79Q40082914-D10D1979-C09D-408B-88A8-8516BC0241DDQ40216566-3A38A707-0A3B-452E-B23E-BD40525EF74DQ40416064-ACFDF462-9A4C-49F2-9C89-6172321DCDE9Q49361412-97378F8B-6B5A-4A87-B7B3-469E8CF18B73Q49575441-7F904C78-8D3C-45EF-A268-F2437273DCACQ52365721-DE3FBC54-53F1-4D82-B7C3-C18E1E287C99Q53932344-79387A14-3AF1-46CD-ADDB-E75BCF26490BQ55447639-FEC3A6C0-EAF0-408F-BA5E-7ABA627F64BCQ58780345-F83AC1F1-FCE5-44B5-9320-74E60DAC3D5D
P2860
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@ast
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@en
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@nl
type
label
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@ast
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@en
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@nl
prefLabel
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@ast
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@en
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@nl
P2860
P3181
P356
P1476
Effectiveness of Palivizumab i ...... dren: A Real-World Perspective
@en
P2093
Adam Jaffe
William Rawlinson
P2860
P304
P3181
P356
10.1155/2014/571609
P407
P577
2014-01-01T00:00:00Z